AMC Entertainment (AMC) reported $1.29 billion in revenue for the quarter ended December 2025, representing a year-over-year decline of 1.4%. EPS of -$0.18 for the same period compares to -$0.18 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $1.28 billion, representing a surprise of +0.5%. The company delivered an EPS surprise of +7.69%, with the consensus EPS estimate being -$0.20.While investors scrutinize revenue and earnings changes year-over-year and how they compare with W ...

For the quarter ended December 2025, Axsome Therapeutics (AXSM) reported revenue of $196 million, up 65% over the same period last year. EPS came in at -$0.71, compared to -$0.96 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $193.01 million, representing a surprise of +1.55%. The company delivered an EPS surprise of -1%, with the consensus EPS estimate being -$0.70.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall ...

Company Performance - Recursion Pharmaceuticals (RXRX) closed at $3.42, reflecting an -8.06% change from the previous day, underperforming the S&P 500 which gained 0.69% [1] - Prior to the latest trading session, RXRX shares had decreased by 25%, lagging behind the Medical sector's gain of 0.77% and the S&P 500's loss of 1% [1] Upcoming Financial Results - Recursion Pharmaceuticals is set to announce its earnings on February 25, 2026, with an expected EPS of -$0.28, indicating a 47.17% growth compared to the same quarter last year [2] - Revenue is projected to be $25.5 million, representing a significant 460.44% increase compared to the year-ago quarter [2] Full-Year Estimates - The Zacks Consensus Estimates for RXRX indicate expected earnings of -$1.59 per share and revenue of $64.62 million, reflecting year-over-year changes of +5.92% and +9.83%, respectively [3] - Recent modifications to analyst estimates for Recursion Pharmaceuticals suggest positive near-term business trends, with positive revisions seen as a favorable sign for the business outlook [3] Zacks Rank and Industry Performance - Recursion Pharmaceuticals currently holds a Zacks Rank of 2 (Buy), with the Zacks Consensus EPS estimate remaining unchanged over the past month [5] - The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 87, placing it in the top 36% of over 250 industries, indicating strong performance potential [6]

Appian (APPN) reported $202.87 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 21.7%. EPS of $0.15 for the same period compares to $0 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $189.1 million, representing a surprise of +7.28%. The company delivered an EPS surprise of +59.57%, with the consensus EPS estimate being $0.09.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Stree ...

Wall Street analysts expect Nvidia (NVDA) to post quarterly earnings of $1.52 per share in its upcoming report, which indicates a year-over-year increase of 70.8%. Revenues are expected to be $65.56 billion, up 66.7% from the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to a company's earnings release, it is of utmost importance ...

Core Insights - Nice (NICE) reported revenue of $786.5 million for the quarter ended December 2025, marking a year-over-year increase of 9% and exceeding the Zacks Consensus Estimate of $778.66 million by 1.01% [1] - The company's EPS for the same period was $3.24, up from $3.02 a year ago, also surpassing the consensus EPS estimate of $3.21 by 0.84% [1] Revenue Performance - Cloud revenue reached $608.33 million, exceeding the average estimate of $602.26 million by five analysts, representing a year-over-year growth of 13.9% [4] - Services revenue was reported at $140.6 million, below the five-analyst average estimate of $143.83 million, reflecting a year-over-year decline of 6.1% [4] - Product revenue amounted to $37.56 million, surpassing the average estimate of $32.57 million, with a slight year-over-year decrease of 1.2% [4] Stock Performance - Shares of Nice have declined by 12.8% over the past month, in contrast to the Zacks S&P 500 composite's decrease of 0.8% [3] - The stock currently holds a Zacks Rank of 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Viewpoint - Expeditors International (EXPD) is expected to report a decline in quarterly earnings and revenues, with earnings per share projected at $1.46, down 13.1% year-over-year, and revenues forecasted at $2.8 billion, reflecting a decrease of 5.3% compared to the same period last year [1]. Earnings Estimates - There has been no revision in the consensus EPS estimate for the quarter over the last 30 days, indicating that analysts have not changed their initial forecasts during this period [2]. - Revisions to earnings estimates are crucial for predicting investor actions regarding the stock, as empirical research shows a strong correlation between earnings estimate trends and short-term stock price performance [3]. Revenue Projections - Analysts project 'Revenues- Airfreight services' to reach $1.04 billion, indicating a year-over-year decline of 2.6% [5]. - The estimate for 'Revenues- Ocean freight and ocean services' is set at $687.50 million, reflecting a significant decrease of 24.3% from the prior-year quarter [5]. - 'Revenues- Customs brokerage and other services' are forecasted to reach $1.07 billion, showing an increase of 8.6% from the year-ago quarter [5]. Net Revenue Estimates - 'Net revenues- Airfreight services' are expected to be $252.72 million, indicating a slight decline of 0.7% from the year-ago quarter [6]. - Analysts estimate 'Net revenues- Customs brokerage and other services' to reach $485.71 million, reflecting a year-over-year increase of 7.3% [6]. - 'Net revenues- Ocean freight and ocean services' are projected at $184.94 million, indicating a year-over-year decline of 18.7% [7]. Stock Performance - Shares of Expeditors International have shown a return of -8% over the past month, compared to a -0.8% change in the Zacks S&P 500 composite [7]. - With a Zacks Rank of 3 (Hold), EXPD is expected to perform in line with the overall market in the near future [7].

Core Viewpoint - Realty Income Corp. is expected to report quarterly earnings of $1.08 per share, reflecting a 2.9% increase year-over-year, with revenues projected at $1.46 billion, indicating a 9.1% year-over-year growth [1]. Earnings Estimates - Over the last 30 days, the consensus EPS estimate for the quarter has been revised upward by 0.3%, indicating analysts' reassessment of their initial forecasts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and are linked to short-term stock price performance [3]. Revenue Projections - The consensus estimate for 'Revenue- Rental (including reimbursable)' is $1.38 billion, representing a 7.9% increase from the previous year [5]. - 'Revenue- Other' is expected to reach $79.45 million, showing a significant increase of 31.1% year-over-year [5]. - 'Revenue- Rental (excluding reimbursable)' is projected at $1.30 billion, indicating an 8% increase from the prior-year quarter [6]. - 'Revenue- Rental (reimbursable)' is estimated at $84.47 million, reflecting an 11.9% year-over-year change [6]. Depreciation and Amortization - Analysts predict 'Depreciation and amortization' will reach $646.96 million [6]. Stock Performance - Realty Income Corp. shares have returned +5.3% over the past month, contrasting with the Zacks S&P 500 composite's -0.8% change, and the company holds a Zacks Rank 3 (Hold) [6].

Enpro (NPO) reported $295.4 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 14.3%. EPS of $1.99 for the same period compares to $1.57 a year ago.The reported revenue represents a surprise of +5.31% over the Zacks Consensus Estimate of $280.5 million. With the consensus EPS estimate being $1.91, the EPS surprise was +4.01%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine the ...

Core Insights - Halozyme Therapeutics reported a revenue of $451.77 million for the quarter ended December 2025, marking a 51.6% increase year-over-year, while EPS was -$0.24 compared to $1.26 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $448.62 million by 0.7%, but the EPS fell short of the consensus estimate of $2.15 by 111.16% [1] Revenue Breakdown - Product sales, net reached $122.67 million, surpassing the average estimate of $115.69 million by analysts, reflecting a year-over-year increase of 54.6% [4] - Royalties amounted to $257.97 million, slightly below the estimated $262.14 million, but still showing a 51.4% increase compared to the previous year [4] - Revenues from collaboration agreements were reported at $71.13 million, exceeding the average estimate of $61.31 million, representing a 47.5% year-over-year growth [4] Stock Performance - Over the past month, shares of Halozyme Therapeutics have returned +11.6%, contrasting with a -1.4% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]